IndustryCompany release

Halozyme lifts 2026 guidance after Q3 revenue jumps 39% on ENHANZE royalties

🇺🇸 Halozyme Therapeutics, Inc. (HALO) · Thu 05 Nov 2026

Halozyme reported third-quarter revenue of $493.0m, with royalties of $341.0m, and raised its full-year outlook as ENHANZE partner products continued to drive growth.

Halozyme Therapeutics reported results for the quarter ended 30 September 2026 on 5 November, posting total revenue of $493.0m, up 39%. Royalty revenue contributed $341.0m of the total.

The company attributed the growth to sales of products from partners that use its ENHANZE drug-delivery technology, naming VYVGART Hytrulo, DARZALEX SC and Phesgo. On the strength of the quarter, Halozyme raised its 2026 total revenue guidance to a range of $1.860bn to $1.925bn.

Halozyme said it expanded ENHANZE agreements with argenx, Incyte and Janssen during the period, and advanced three programmes into Phase 1 development. The summary provided does not give further detail on the terms of the deals or the identity of the programmes.

The company also pointed to a Dutch court injunction against Merck's Keytruda Qlex relating to an MDASE patent. Separately, it completed a $1.5bn convertible notes offering. Further details of the ruling and the financing were not available in the material reviewed.

What it means for your team

  • Market-access teams should note that royalties from subcutaneous products built on ENHANZE are a major driver of Halozyme's revenue, which reflects continued uptake of these formulations.
  • Regulatory and IP teams may want to follow the Dutch injunction over the MDASE patent, as it concerns a subcutaneous formulation of a major oncology product.
  • Teams working with partners on ENHANZE should watch for details of the expanded deals with argenx, Incyte and Janssen and the three new Phase 1 programmes.

Company's press release (SEC filing): Halozyme Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Halozyme Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →